JPRN-UMIN000032659已完成未知
A phase 2 study of KRd(carfilzomib, lenalidomide, dexamethasone) consolidation for newly diagnosed multiple myeloma - OCHA-KRd
Ochanomizu Hematology Study Group0 个研究点目标入组 21 人开始时间: 2018年5月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 66years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. MRD in the BM is absent(<10*-4) after ASCT. 2. Patient who has hypersensitivity to the study drugs. 3. Uncontrolled or severe cardiovascular disease, including New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, or cardiac amyloidosis. 4. Uncontrolled hypertention. 5. Uncontrolled active infection. 6. Past history of pulmonary embolism, myocardial infarction and cerebral infarction. 7. Past history of deep vein thrombosis, administration of anticoagulants and/or antiplatelet drugs within 3 years 8. HBs antigen positive and/or HCV positive. 9. Administration of HBV reatctivation. 10. Active advanced-stage cancer. 11. Female patient who is pregnant and/or breastfeeding. 12. Active gastrointestinal bleeding. 13. Past history of renal transplantation. 14. Uncontrolled diabetes mellitus. 15. Serious psychiatric illness 16. Patient who is judged to be medically unfit by his/her physician.
研究者
相似试验
招募中
不适用
Phase II study of carfilzomib, pomalidomide, and dexamethasone for multiple myeloma patients who had relapsed or progressed after carfilzomib, lenalidomide, and dexamethasone (KAPPA trial)NeoplasmsKCT0006285Samsung Medical Center33
招募中
2 期
Study to evaluate the effectiveness of a combination of 3 treatments, followed by transplantation of their own blood cell progenitor cells for patients under 70 years of age with asymptomatic multiple myeloma at high risk of developing into symptomatic myeloma2024-516908-42-00Fundacion PETHEMA90
进行中（未招募）
1 期
se of a novel chemotherapeutic regimen in an attempt to eradicate residual myeloma disease after a first autologous stem cell Transplantation.MedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2016-004778-16-ATDepartment of Medicine I, Ordensklinikum Linz, Elisabethinen Hospital Linz41
进行中（未招募）
1 期
A randomized trial that compares Carfilzomib - Lenalidomide - Dexamethasone (KRd) versus Lenalidomide - Dexamethasone (Rd) in new diagnosed myeloma patients not elegible for trasplant.PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCTMedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104CTIS2024-513396-41-00Fondazione European Myeloma Network Italy O.N.L.U.S.340
招募中
3 期
A randomized trial that compares Carfilzomib - Lenalidomide - Dexamethasone (KRd) versus Lenalidomide - Dexamethasone (Rd) in new diagnosed myeloma patients not elegible for trasplant.2024-513396-41-00Fondazione European Myeloma Network Italy O.N.L.U.S.340